This January, Johnson & Johnson (Pty) LtdDePuy Synthes announced it received US Food and Drug Administration 510(k) clearance for the VELYS Robotic-Assisted Solution designed for use with the Attune knee system. The solution simplifies surgeon’s workflow around total knee replacement and is part of the broader VELYS digital surgery platform of connected technologies, which can leverage data insights for patients, surgeons and health systems.
Exec Chat: J&J DePuy Synthes’ Sharrolyn Josse Outlines Strategy For VELYS Digital Surgery
In an interview with Medtech Insight, Sharrolyn Josse, worldwide president of VELYS Digital Surgery and Capital at Johnson & Johnson’s DePuy Synthes unit, outlines strategies that are driving the present and future VELYS robotic-assisted solution and its connected technologies.

More from Digital Technologies
Beyond the US market, Monogram is actively pursuing regulatory approvals abroad, with India as a key target. The company has partnered with Shalby Hospitals, one of India’s largest orthopedic hospital networks, to conduct clinical trials and accelerate regulatory clearance in the region.
AdvaMed’s top priorities for the 119th Congress include modernizing US Medicare services and expanding patients’ access to the latest medical technologies.
Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."
Exer Labs Inc.’s website marketed its AI-based Exer Scan app to “screen and treat Parkinson’s, TB, Cerebral Palsy and more.” But those claims went well beyond what was allowed under the product’s 510(k) clearance, US regulators say.
More from Medtech Insight
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.